OMDA
Omada Health Inc
$23.97
▲ 0.9%Updated Aug 19, 11:10 AM ET
OMDA at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
-4.0%
Interest Coverage
—
Current Ratio
3.91x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Omada Health Inc (OMDA) is a small-cap company in the Health Care industry, part of the Health Care sector of the S&P 500.
In its latest reported year it generated about $260.21M in revenue and posted a net loss of $12.78M.
Our model rates OMDA Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
2Y CAGR
45.6%
Revenue moved from $122.78M in 2023 to $260.21M in 2025, a 45.6% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
65.7%
Operating Margin
-4.6%
Net Margin
-4.9%
ROE
—
Total Debt
$0.00
Net Debt
-$221.71M
Net cash position
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 3.9x. Detailed balance-sheet leverage is limited for this name. It carries roughly $0.00 of total debt against $221.71M of cash.
Operating CF
$18.25M
Free Cash Flow
$16.93M
FCF Margin
6.5%
In the latest year Omada Health Inc produced about $18.25M of operating cash flow and $16.93M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
OMDA trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$4.75
Current price
$23.97
Starting FCF (latest 10-K)
$16.93M
Growth, years 1–5
4.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where OMDA sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How OMDA stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), OMDA ranks #244 of 324 by our overall rating.
P/E vs sector
—
median 27.3x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#244
of 324 by rating
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $23.97 today · expected CAGR -38% – -31%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $281.03M | $303.51M | $327.79M | $354.01M | $382.33M |
| Net income | $8.43M | $9.11M | $9.83M | $10.62M | $11.47M |
| EPS | $0.14 | $0.15 | $0.16 | $0.17 | $0.19 |
| Share price (low) | $1.65 | $1.78 | $1.93 | $2.08 | $2.25 |
| Share price (high) | $2.75 | $2.97 | $3.21 | $3.47 | $3.75 |
| CAGR (low–high) | -93% / -89% | -73% / -65% | -57% / -49% | -46% / -38% | -38% / -31% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for OMDA:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against OMDA:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Omada Health Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 18 Wall Street analysts covering OMDA recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
OMDA's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
OMDA — frequently asked questions
Is OMDA a good stock to buy?
We don't give buy or sell advice. Review Omada Health Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does OMDA's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Omada Health Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for OMDA calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this OMDA analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell OMDA. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.